journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/28206829/validity-of-low-contrast-letter-acuity-as-a-visual-performance-outcome-measure-for-multiple-sclerosis
#1
Laura J Balcer, Jenelle Raynowska, Rachel Nolan, Steven L Galetta, Raju Kapoor, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn Hudson, Richard Rudick
Low-contrast letter acuity (LCLA) has emerged as the leading outcome measure to assess visual disability in multiple sclerosis (MS) research. As visual dysfunction is one of the most common manifestations of MS, sensitive visual outcome measures are important in examining the effect of treatment. Low-contrast acuity captures visual loss not seen in high-contrast visual acuity (HCVA) measurements. These issues are addressed by the MS Outcome Assessments Consortium (MSOAC), including representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28206828/validity-of-the-timed-25-foot-walk-as-an-ambulatory-performance-outcome-measure-for-multiple-sclerosis
#2
Robert W Motl, Jeffrey A Cohen, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with multiple sclerosis (MS). One of the MSOAC goals is acceptance and qualification by regulators of performance outcomes that are highly reliable and valid, practical, cost-effective, and meaningful in MS...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28206827/validity-of-the-symbol-digit-modalities-test-as-a-cognition-performance-outcome-measure-for-multiple-sclerosis
#3
Ralph Hb Benedict, John DeLuca, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick
Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine the efficacy of treatment. The increasing focus of new therapies on slowing progression or reversing neurological disability makes the utilization of sensitive, reproducible, and valid measures essential. Processing speed is a basic elemental cognitive function that likely influences downstream processes such as memory. The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28206826/the-nine-hole-peg-test-as-a-manual-dexterity-performance-measure-for-multiple-sclerosis
#4
Peter Feys, Ilse Lamers, Gordon Francis, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick
Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis (MS) and is increasingly prevalent with worsening disease. While various tests and patient-reported outcome measures are available, the Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The MS Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28206813/the-measure-tells-the-tale-clinical-outcome-measures-in-multiple-sclerosis
#5
Hanneke E Hulst, Alan J Thompson, Jeroen Jg Geurts
No abstract text is available yet for this article.
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28185472/involvement-of-peripheral-iii-nerve-in-multiple-sclerosis-patient-report-of-a-new-case-and-discussion-of-the-underlying-mechanism
#6
Natalia Shor, Maria Del Mar Amador, Didier Dormont, Catherine Lubetzki, Anne Bertrand
Multiple sclerosis (MS) is a chronic disorder that affects the central nervous system myelin. However, a few radiological cases have documented an involvement of peripheral cranial nerves, within the subarachnoid space, in MS patients. We report the case of a 36-year-old female with a history of relapsing-remitting (RR) MS who consulted for a subacute complete paralysis of the right III nerve. Magnetic resonance imaging (MRI) examination showed enhancement and thickening of the cisternal right III nerve, in continuity with a linear, mesencephalic, acute demyelinating lesion...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28185471/peripheral-nervous-system-involvement-in-multiple-sclerosis
#7
Alex Rovira
No abstract text is available yet for this article.
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28169581/gray-matter-trophism-cognitive-impairment-and-depression-in-patients-with-multiple-sclerosis
#8
Emanuele Pravatà, Maria A Rocca, Paola Valsasina, Gianna C Riccitelli, Claudio Gobbi, Giancarlo Comi, Andrea Falini, Massimo Filippi
BACKGROUND: Cognitive impairment and depression frequently affects patients with multiple sclerosis (MS). However, the relationship between the occurrence of depression and cognitive impairment and the development of cortical atrophy has not been fully elucidated yet. OBJECTIVES: To investigate the association of cortical and deep gray matter (GM) volume with depression and cognitive impairment in MS. METHODS: Three-dimensional (3D) T1-weighted scans were obtained from 126 MS patients and 59 matched healthy controls...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28165298/methylphenidate-is-likely-less-effective-than-placebo-for-improving-imbalance-walking-and-fatigue-in-people-with-multiple-sclerosis
#9
Michelle H Cameron, Garnett McMillan
No abstract text is available yet for this article.
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28155575/similar-birth-cohort-patterns-in-crohn-s-disease-and-multiple-sclerosis
#10
Amnon Sonnenberg, Vladeta Ajdacic-Gross
BACKGROUND: The etiology of Crohn's disease and multiple sclerosis is unknown. Genetic susceptibility and environmental factors are believed to play a role in both diseases. OBJECTIVES: To compare the long-term time trends of the two diseases and thus gain insight about their etiology. METHODS: We analyzed mortality data of Crohn's disease and multiple sclerosis from Canada, England, Italy, the Netherlands, Switzerland, and the United States during the past 60 years...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28155573/oral-contraceptives-and-ms-disease-activity-in-a-contemporary-real-world-cohort
#11
Riley Bove, Kelsey Rankin, Alicia S Chua, Taylor Saraceno, Neda Sattarnezhad, Emily Greeke, Fiona Stuart, Allison LaRussa, Bonnie I Glanz, Tanuja Chitnis
BACKGROUND: There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course. OBJECTIVE: To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT). METHODS: From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28151074/a-systematic-review-of-the-effects-of-modifiable-risk-factor-interventions-on-the-progression-of-multiple-sclerosis
#12
Susanne Hempel, Glenn D Graham, Ning Fu, Elena Estrada, Annie Y Chen, Isomi Miake-Lye, Jeremy N V Miles, Roberta Shanman, Paul G Shekelle, Jessica M Beroes, Mitchell T Wallin
BACKGROUND: Several risk factors are associated with multiple sclerosis (MS) progression and may be amenable to intervention. OBJECTIVE: To systematically review the evidence for interventions targeting risk factors for MS progression. METHODS: We searched six databases and existing reviews till March 2015 and consulted with experts to identify randomized controlled trials (RCTs) of interventions targeting MS risk factors (PROSPERO 2015:CRD42015016461)...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28151053/a-systematic-review-of-modifiable-risk-factors-in-the-progression-of-multiple-sclerosis
#13
Susanne Hempel, Glenn D Graham, Ning Fu, Elena Estrada, Annie Y Chen, Isomi Miake-Lye, Jeremy N V Miles, Roberta Shanman, Paul G Shekelle, Jessica M Beroes, Mitchell T Wallin
BACKGROUND: The presenting symptoms and rate of progression of multiple sclerosis (MS) are very heterogeneous. The diverse clinical manifestations and the clinical course of the disease may vary with modifiable risk factors. OBJECTIVE: To systematically review modifiable risk factors and exposures associated with MS progression. METHODS: We searched six databases till March 2015, reference-mined reviews, and consulted with experts (PROSPERO 2015:CRD42015016461)...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28178867/the-relationship-between-white-matter-fiber-damage-and-gray-matter-perfusion-in-large-scale-functionally-defined-networks-in-multiple-sclerosis
#14
Ashley Y Ma, Rita C Vitorino, Seyed-Parsa Hojjat, Alannah D Mulholland, Liying Zhang, Liesly Lee, Timothy J Carroll, Charles G Cantrell, Chase R Figley, Richard I Aviv
BACKGROUND: Recent studies utilizing perfusion as a surrogate of cortical integrity show promise for overall cognition, but the association between white matter (WM) damage and gray matter (GM) integrity in specific functional networks is not previously studied. OBJECTIVE: To investigate the relationship between WM fiber integrity and GM node perfusion within six functional networks of relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28156186/polyunsaturated-fatty-acids-and-the-risk-of-multiple-sclerosis
#15
Kjetil Bjørnevik, Tanuja Chitnis, Alberto Ascherio, Kassandra L Munger
BACKGROUND: Results from previous studies on polyunsaturated fatty acid (PUFA) intake and multiple sclerosis (MS) risk are conflicting. OBJECTIVE: To prospectively investigate the association between dietary intake of PUFA and MS risk. METHODS: We followed 80,920 women from Nurses' Health Study (1984-2004) and 94,511 women from Nurses' Health Study II (1991-2009) who reported on diet using a validated food frequency questionnaire every 4 years and identified 479 incident MS cases during follow-up...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28156185/evidence-of-activation-of-the-nrf2-pathway-in-multiple-sclerosis-patients-treated-with-delayed-release-dimethyl-fumarate-in-the-phase-3-define-and-confirm-studies
#16
Sreeja Gopal, Alvydas Mikulskis, Ralf Gold, Robert J Fox, Katherine T Dawson, Lakshmi Amaravadi
BACKGROUND: Delayed-release dimethyl fumarate (DMF) is an approved oral treatment for relapsing forms of multiple sclerosis (MS). Preclinical studies demonstrated that DMF activated the nuclear factor E2-related factor 2 (Nrf2) pathway. DMF and its primary metabolite monomethyl fumarate (MMF) were also shown to promote cytoprotection of cultured central nervous system (CNS) cells via the Nrf2 pathway. OBJECTIVE: To investigate the activation of Nrf2 pathway following ex vivo stimulation of human peripheral blood mononuclear cells (PBMCs) with DMF or MMF, and in DMF-treated patients from two Phase 3 relapsing MS studies DEFINE and CONFIRM...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28155580/age-related-multiple-sclerosis-severity-score-disability-ranked-by-age
#17
Ali Manouchehrinia, Helga Westerlind, Elaine Kingwell, Feng Zhu, Robert Carruthers, Ryan Ramanujam, Maria Ban, Anna Glaser, Stephen Sawcer, Helen Tremlett, Jan Hillert
BACKGROUND: The Multiple Sclerosis Severity Score (MSSS) is obtained by normalising the Expanded Disability Status Scale (EDSS) score for disease duration and has been a valuable tool in cross-sectional studies. OBJECTIVE: To assess whether use of age rather than the inherently ambiguous disease duration was a feasible approach. METHOD: We pooled disability data from three population-based cohorts and developed an Age Related Multiple Sclerosis Severity (ARMSS) score by ranking EDSS scores based on the patient's age at the time of assessment...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28140753/reduced-brain-atrophy-rates-are-associated-with-lower-risk-of-disability-progression-in-patients-with-relapsing-multiple-sclerosis-treated-with-cladribine-tablets
#18
Nicola De Stefano, Antonio Giorgio, Marco Battaglini, Alessandro De Leucio, Christine Hicking, Fernando Dangond, Gavin Giovannoni, Maria Pia Sormani
BACKGROUND: Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage. METHODS: In the CLARITY study ( ClinicalTrials.gov NCT00213135), the effect of 2 years' treatment with cladribine tablets on annualized percentage brain volume change (PBVC/y) was evaluated in patients with relapsing MS (RMS). RESULTS: Compared with placebo (-0...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28098510/dt-mri-microstructural-cortical-lesion-damage-does-not-explain-cognitive-impairment-in-ms
#19
Paolo Preziosa, Elisabetta Pagani, Maria E Morelli, Massimiliano Copetti, Vittorio Martinelli, Fiammetta Pirro, Andrea Falini, Giancarlo Comi, Massimo Filippi, Maria A Rocca
OBJECTIVE: We combined double inversion recovery (DIR) and diffusion tensor (DT) magnetic resonance imaging (MRI) to quantify the severity of cortical lesion (CL) microstructural tissue abnormalities in a large cohort of relapse-onset multiple sclerosis (MS) patients and its contribution to cognitive dysfunction. METHODS: DIR, DT, dual-echo, and three-dimensional (3D) T1-weighted scans were acquired from 149 MS patients and 40 controls. Cognitively impaired (CI) patients had ⩾2 abnormal neuropsychological tests...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28090800/similar-familial-risk-in-multiple-sclerosis-subgroups
#20
Jie Song, Virginija Karrenbauer, Ali Manouchehrinia, Catarina Almqvist, Jan Hillert, Helga Westerlind
BACKGROUND: A subgroup of patients diagnosed with multiple sclerosis (MS) present with no oligoclonal bands (OCB) in the cerebrospinal fluid (CSF). Several studies report different clinical characteristics and genetic associations between the two groups. OBJECTIVE: To investigate whether the OCB negative subgroup has a distinct etiology from band positive MS. METHODS: Using nationwide registers to estimate familial risks, which reflect the genetic contribution of a disease...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"